Trial Profile
Randomized, Placebo-controlled, Double-blind Phase 2 Study of Patritumab (U3-1287) in Combination With Cetuximab Plus Platinum-based Therapy in First Line Setting in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Patritumab (Primary) ; Carboplatin; Cetuximab; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 12 Oct 2019 Primary endpoint has not been met. (Progression Free Survival (PFS) in the Heregulin (HRG)-High Expression Population)
- 12 Oct 2019 Results evaluating safety, efficacy and pharmacokinetics of first-line cetuximab plus cisplatin or carboplatin with either patritumab or placebo in patients with squamous cell carcinoma of the head and neck published in the European Journal of Cancer
- 12 Dec 2018 Status changed to discontinued.